Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment
Dow Drops 138 Points On Losses For Shares Of American Express, Merck
Investors in Merck (NYSE:MRK) Have Seen Respectable Returns of 48% Over the Past Three Years
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios
Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds?
Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints
Merck Says Experimental RSV Treatment Protected Infants in Trial, Paving Way for Potential Approval
Merck's Posts More Positive Clesrovimab RSV Candidate Study Data
Express News | Merck: Interim Analysis of a Phase 3 Trial Showed Clesrovimab Had Comparable Safety Profile to Palivizumab in Infants & Children
Express News | Merck’s Clesrovimab (Mk-1654), an Investigational Respiratory Syncytial Virus (Rsv) Preventative Monoclonal Antibody, Significantly Reduced Incidence of Rsv Disease and Hospitalization in Healthy Preterm and Full-Term Infants
Express News | Merck: In Phase 2B/3 Trial Clesrovimab Reduced Rsv-Associated Lower Respiratory Infection Hospitalizations by Over 90% Through 5 Months
Merck (MRK): Promising Long-Term Stock With Strategic Acquisitions
Merck & Co Analyst Ratings
Bernstein: First coverage of eli lilly and co, gilead sciences, and amgen all rated as "outperforming the large cap".
Bernstein initiated coverage on eli lilly and co, gilead sciences, and amgen, all with an 'outperform' rating. Bernstein stated that the bullish rating on gilead and amgen is based on optimistic expectations for key assets to achieve revenue growth from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it leverages the cash obtained from weight loss drugs", eli lilly and co is ready to use a diversified investment portfolio and leverage weight loss drugs for growth. In addition, Bern
Here's What to Expect From Merck & Co.'s Next Earnings Report
Express News | Merck & Co Inc : Bernstein Initiates Coverage With Market-Perform Rating; Target Price $115
Bernstein starts to focus on US pharmaceutical stocks, giving Eli Lilly and Co (LLY.US) and others a "outperforming the large cap" rating.
Bernstein starts covering Eli Lilly and Co (LLY.US), Gilead Sciences (GILD.US), and Amgen (AMGN.US), all with an "outperform" rating.
merck's new drug for pulmonary arterial hypertension has applied for market approval in China.
merck's application for the injection sotatercept has been accepted for market approval.